GlaxoSmithKline’s drug ‘offers quick and lasting migraine relief’

GlaxoSmithKline’s (GSK’s) migraine treatment Treximet is a more effective method of pain relief than its individual components.

Two studies of more than 2,900 people who suffer from migraines proved the drug offers “superior efficacy” when compared to the pain relief offered by sumatriptan 85mg and naproxen sodium 500mg.

Not only was the drug found to be an effective, but it was also found to be able to maintain pain relief for between two and 24 hours.

According to GSK, Treximet is the first single-tablet migraine treatment that combines its pioneering class of triptan migraine medicines with an anti-inflammatory pain reliever.

Dr Stephen Silberstein, clinical trial participant and professor of neurology at Thomas Jefferson University, said migraine patients want treatments to bring swift and lasting relief.

He added that Treximet proved in clinical trials that it offers “sustained migraine pain relief for a significant number of patients”.

GSK launched its first over-the-counter triptan remedies in 2006. At the time, Frances Crewdson of the firm said triptans have had a “massive” impact on many migraine sufferers’ lives as they are a “powerful option” to stop migraines.